SCHEMBL617331

SCHEMBL617331

CCOC(=O)C(=[N+]=[N-])C(=O)c1sccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
KMT2A Q03164 4/20 0.40
HTT P42858 1/20 0.40
GAA P10253 5/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 2/20 0.37
PKM P14618 5/20 0.36
NPSR1 Q6W5P4 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
GSK3B P49841 1/20 0.35
PTPN1 P18031 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
GPR35 Q9HC97 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10164986 0.86 PKM (0.47) ALDH1A1KMT2AGAAMAPTKDM4E
SCHEMBL7043180 0.84 ALDH1A1 (0.46) ALDH1A1KMT2AHTTGAAMAPT
SCHEMBL616878 0.76 ABCB1 (0.40) ALDH1A1KMT2AHTTGAAMAPT
SCHEMBL616879 0.76 ABCB1 (0.40) ALDH1A1KMT2AHTTGAAMAPT
SCHEMBL13193377 0.76 ALDH1A1 (0.44) ALDH1A1KMT2AHTTGAAMAPT
SCHEMBL28353721 0.75 CES2 (0.47) ALDH1A1KMT2AMAPTKDM4ENPSR1
SCHEMBL884798 0.75 CES2 (0.47) ALDH1A1KMT2AMAPTLMNAGPR35
SCHEMBL240151 0.75 ALDH1A1 (0.49) ALDH1A1KMT2AHTTGAAMAPT
SCHEMBL3709449 0.71 CYP11B1 (0.43) ALDH1A1KMT2AGAAMAPTKDM4E
SCHEMBL1437430 0.71 TSHR (0.38) ALDH1A1KMT2AGAAMAPTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421366-B1 HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2013-08-28 EP disclosed
US-8293744-B2 Heterocyclic fused cinnoline M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2012-10-23 US disclosed
EP-2421366-A1 HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2012-02-29 EP disclosed
US-20120040978-A1 Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME CORP. (US) 2012-02-16 US disclosed
WO-2010123716-A1 HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040978-A1 Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators CHRM1, CNR1, CHRNA7 ALDH1A1 1911/4885KMT2A 2415/4885HTT 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.